![Dipal Doshi](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 2 M $ al 31/05/2026
Dipal Doshi is Chief Executive Officer & Director at Entrada Therapeutics, Inc. since 2024.
Director at ashibio, Inc. since 2024.
Independent Director at Azenta, Inc. starting 2025.
Member of Aspen Global Leadership Network.
Formerly Director at The Children's Health Fund.
Head-Corporate Development at Catalent Pharma Solutions, Inc. from 2005 to 2007.
Senior Vice President at Auven Therapeutics Management LLLP from 2008 to 2013.
Principal at Merrill Lynch & Co., Inc. from 2004 to 2007.
Senior VP-Business Planning & Development at Amicus Therapeutics, Inc. from 2014 to 2017.
Principal at Eli Lilly & Co. Ltd. from 2001 to 2003.
Vice President at Celtic Pharma Management LP.
General Manager at Scioderm, Inc. Education includes undergraduate degree from Rutgers State University of New Jersey and MBA from The Wharton School of the University of Pennsylvania.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
ENTRADA THERAPEUTICS INC 0,53 % | 13/04/2026 | 206.096 ( 0,53 % ) | 1 M $ | 31/05/2026 |
AZENTA, INC. 0,02 % | 05/02/2026 | 9.703 ( 0,02 % ) | 222 005 $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| ENTRADA THERAPEUTICS, INC. | Director Ejecutivo | 01/08/2017 |
| AZENTA, INC. | Director/Miembro de la Junta | 30/01/2025 |
Aspen Global Leadership Network | Corporate Officer/Principal | - |
ashibio, Inc.
 ashibio, Inc. Pharmaceuticals: MajorHealth Technology Develops novel therapies for patients with rare bone and connective tissue disorders | Director/Miembro de la Junta | 17/09/2024 |
| Empresas | Cargo | Fin |
|---|---|---|
| AMICUS THERAPEUTICS, INC. | Corporate Officer/Principal | 01/08/2017 |
Auven Therapeutics Management LLLP
 Auven Therapeutics Management LLLP Investment ManagersFinance Auven Therapeutics Management focuses on acquiring novel, life-saving and quality of life-enhancing products and accelerating the development of these products. They take ownership and control of the development of carefully selected clinical-stage therapeutic assets in order to build value around them to the point where they are attractive acquisition opportunities for established pharmaceutical and biotechnology companies. | Corporate Officer/Principal | 01/01/2013 |
Catalent Pharma Solutions, Inc.
 Catalent Pharma Solutions, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and sells pharmaceutical products | Corporate Officer/Principal | 31/12/2007 |
Merrill Lynch & Co., Inc. /Old/
 Merrill Lynch & Co., Inc. /Old/ Investment Banks/BrokersFinance Provides wealth management, securities trading and sales, corporate finance and investment banking services | Corporate Officer/Principal | 31/12/2007 |
Eli Lilly & Co. Ltd.
 Eli Lilly & Co. Ltd. Pharmaceuticals: MajorHealth Technology Provides pharmaceutical health care solutions | Corporate Officer/Principal | 01/01/2003 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 14 |
|---|---|
Merrill Lynch & Co., Inc. /Old/
Merrill Lynch & Co., Inc. /Old/ Investment Banks/BrokersFinance Provides wealth management, securities trading and sales, corporate finance and investment banking services | Finance |
Azenta, Inc.
 Azenta, Inc. Medical/Nursing ServicesHealth Services Provides gene sequencing and gene synthesis services and develops automated ultra-cold storage systems | Health Services |
Amicus Therapeutics, Inc.
 Amicus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures novel medicines for rare diseases | Health Technology |
Scioderm, Inc.
 Scioderm, Inc. BiotechnologyHealth Technology Engages in the development of innovative therapies for areas of high unmet need, including orphan products | Health Technology |
Rutgers State University of New Jersey
 Rutgers State University of New Jersey Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Children's Health Fund
 The Children's Health Fund Medical/Nursing ServicesHealth Services Provides health care services | Health Services |
Eli Lilly & Co. Ltd.
Eli Lilly & Co. Ltd. Pharmaceuticals: MajorHealth Technology Provides pharmaceutical health care solutions | Health Technology |
Celtic Pharma Management LP
 Celtic Pharma Management LP Investment ManagersFinance Celtic Pharma invests in life sciences companies located in Bermuda. The firm targets companies operating in the fields of biotechnology, pharmaceuticals and biological drugs. It provides financing for later stage companies and also takes controlling interest. | Finance |
Catalent Pharma Solutions, Inc.
Catalent Pharma Solutions, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and sells pharmaceutical products | Health Technology |
Auven Therapeutics Management LLLP
Auven Therapeutics Management LLLP Investment ManagersFinance Auven Therapeutics Management focuses on acquiring novel, life-saving and quality of life-enhancing products and accelerating the development of these products. They take ownership and control of the development of carefully selected clinical-stage therapeutic assets in order to build value around them to the point where they are attractive acquisition opportunities for established pharmaceutical and biotechnology companies. | Finance |
The Wharton School of the University of Pennsylvania
 The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aspen Global Leadership Network | |
Entrada Therapeutics, Inc.
 Entrada Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics for rare neuromuscular diseases | Health Technology |
ashibio, Inc.
ashibio, Inc. Pharmaceuticals: MajorHealth Technology Develops novel therapies for patients with rare bone and connective tissue disorders | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
